- Research article
- Open Access
- Open Peer Review
Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro
- Valentina Masola†1,
- Amedeo Carraro†2Email author,
- Gianluigi Zaza1,
- Gloria Bellin1,
- Umberto Montin2,
- Paola Violi2,
- Antonio Lupo1 and
- Umberto Tedeschi2
© Masola et al. 2015
- Received: 28 October 2014
- Accepted: 9 September 2015
- Published: 14 September 2015
Everolimus (EVE), a mammalian target of rapamycin inhibitor, has been proposed as liver transplant immunosuppressive drug, gaining wide interest also for the treatment of cancer. Although an appropriate tolerance, it may induce several adverse effects, such as fibro-interstitial pneumonitis due to the acquisition of activated myofibroblasts. The exact molecular mechanism associated with epithelial to mesenchymal transition (EMT) may be crucial also in the liver context. This work examines the role and the molecular mediators of EMT in hepatic stellate cell (HSC) and human liver cancer cells (HepG2) and the potential role of EVE to maintain the epithelial phenotype rather than to act as a potential initiators of EMT.
Real time-PCR and western blot have been used to assess the capability of EVE at low-therapeutic (10 nM) and high (100 nM) dose to induce an in vitro EMT in HSC and HepG2.
Biomolecular experiments demonstrated that low concentration of EVE (10 nM) did not modify the gene expression of alpha-smooth muscle actin (α-SMA), Vimentin (VIM), Fibronectin (FN) in both HSC and HepG2 cells, whereas EVE at 100 nM induced a significant over-expression of all the three above-mentioned genes and an increment of α-SMA and FN protein levels. Additionally, 100 nM of EVE induced a significant phosphorylation of AKT and an up-regulation of TGF-β expression in HSC and HepG2 cells.
Our data, although obtained in an in vitro model, revealed, for the first time, that high concentration of EVE may induce EMT in liver cells confirming previous published evidences obtained in renal cells. Additionally, they suggested that mTOR-I should be administered at the lowest dose able to maximize their important and specific therapeutic properties minimizing or avoiding fibrosis-related adverse effects.
In summary, if confirmed by additional studies, our results could be useful for researchers to standardize new therapeutic immunosuppressive and anticancer drugs protocols.
- HepG2 Cell
- Mantle Cell Lymphoma
- Hepatic Stellate Cell
- Human Liver Cancer Cell
Standard immunosuppressive strategies after liver transplantation are based on steroids in combination with mycophenolic acid or calcineurin inhibitors (CNI); however their use might be associate with relevant side effects, most of all chronic renal failure, with an incidence of up to 20 % . The mTOR inhibitor and immunosuppressant Everolimus (EVE), in contrast with CNI, is associated with a low nephrotoxicity . EVE belongs to the rapamycin class of drugs that are allosteric inhibitors of mTORC1, an inhibitor of proliferative signal. The main mechanism of action of this drug is the inhibition of mTORC1 complex, a regulatory protein kinase involved in lymphocyte proliferation and other developmental processes [3, 4]. EVE has gained wide interest also in other fields, for example, for the treatment of cancer, switching to less invasive phenotype of tumoral cells and inhibiting angiogenesis [5, 6]. Then, due to this activity it has been proposed in de novo and maintenance liver transplant immunosuppressive protocols to prevent or treat hepatocarcinoma (HCC) recurrence, with survival benefits [7, 8]. From the cellular point of view, interestingly, mTOR signaling is also involved in the mechanism of quiescent hepatic stellate cells (HSC) activation . For this reason, the potential role of mTOR-I in attenuating fibrogenic pathways has been already examined in experimental models, showing a reduced accumulation of extracellular matrix (ECM)-producing cells and ECM components . Then, in consideration of the role played by mTOR-I against proliferation and fibrogenesis, we can suppose that it could alleviate liver fibrosis also in the transplanted graft. Liver fibrosis, which is evident in 75 % of biopsies performed in long-term liver transplant (LTx) survivors, may be promoted by the recurrence of native disease (HCV), hepatotoxicity, de novo disease, non-alcoholic steatohepatitis, chronic rejection and vascular or biliary complications . However, despite evident clinical and experimental advantages of this drug category, mTOR-I may induce the development of several systemic side effects including hematological disorders (anemia, leukopenia and thrombocytopenia), dismetabolism (hyperlipidemia, post-transplant diabetes), lymphedema, stomatitis and fertility/gonadic toxicity [12–14]. Fibrosis related pulmonary adverse effects (e.g., lymphocytic interstitial pneumonitis, bronchiolitis obliterans with organizing pneumonia and focal pulmonary fibrosis) have been also showed in the last years by several reports in oncological and renal transplant patients treated with mTOR-I [15–18]. Our in vitro experimental study has already evaluated novel cellular aspects of the potential pro-fibrotic activity of EVE in kidney, showing, for the first time, that epithelial to mesenchymal transition (EMT) in renal tubular cells may be activated by high doses of EVE . It is well known that EMT, a phenotypic conversion of epithelium to a fibroblastic or myofibroblastic phenotype, may have a pivotal role to induce fibrogenesis also in the liver microenviroment . In this context, rearranged ECM by migratory processes induced by EMT appears to be of particular importance also in the mechanism of HCC invasion. In fact, a key event in the development and progression of cancer is the potential of tumor cells to migrate and invade into surrounding tissues. As regards, involvement of PI3K/Akt/mTOR pathway in the interactions between HCC cells and non-parenchymal cells, such as mesenchymal stem cell (MSC), are critical issues for disease progression . Therefore, the aim of our study has been to analyze whether EVE at low-therapeutic [10 nM (corresponding to 3-8 ng/mL serum level)] and high (100 nM) doses might be able to induce in vitro EMT in human hepatoblastoma cells (HepG2) and to activate hepatic stellate cells (HSC). This work prompted us to assess the use of EVE in order to optimize its role in a tailored immunosuppressive regimen.
Cell culture and treatments
HepG2 (human liver cancer cells) were purchased from ATCC and maintained in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA, USA). The medium was supplemented with 10 % fetal bovine serum (FBS) and 1 % antibiotic penicillin/streptomycin. Cells were maintained at 37 °C, 5 % CO2 humidified incubator.
Hepatic stellate cells (HSC) were isolated from normal male Winstar rats. All animals were purchased from Charles River Laboratories and were housed in the Animal research Facility of Biological-Chemistry Department. They were maintained under a 12-h light–dark cycle and given rat chow and water ad libitum. The animal investigation was in accordance with the National Institute of Health guidelines for the care of Laboratory animals and was approved by the local committee for supervision of animal experiments at the University Hospital of Padova, Italy. This is over and above adherence to general guidelines.
HSCs were isolated from normal livers according to a modified Zhang method ; livers were perfused with a calcium-free buffer solution to wash out the blood, subsequently with a wash solution (calcium-free solution with CaCl2 0.294 g/L, MgSO4 0.097 g/L) and finally incubated in a digestion buffer (collagenase 0.6 g/L in Gey’s Balanced Salt Solution with Ca2+and Mg2+, pH 7.5) for 1 h (37 °C, CO2 5 %) to digest the extracellular matrix. The organs were cut into small pieces and subjected to homogenization to produce a single cell-suspension, which was centrifuged at 1450 × g for 18 min in 12 % (wt/vol) Nycodenz gradient to obtain a pure HSC fraction. Both the number and viability of HSCs were determined using the trypan blue dye exclusion test.
Collected HSCs were washed with Hank’s balanced salt solution and resuspended at a concentration of 1 × 105 cells/ml, in DMEM (supplemented with 20 % FBS and 1× antibiotic solution) and cultured on collagen type I coated well plates (10 μg/ml) in a 5 % CO2-humidified atmosphere. Serum-starved cells were subsequently detached for experiments using trypsin/EDTA solution.
All cell experiments were performed between passages 3 and 4.
Everolimus was kindly provided by Novartis (Basel, Switzerland) and dissolved in DMSO according to the manufacturer’s instructions.
HepG2 and HSC cells were plated in complete growth medium and then starved for 24 h in serum free medium. Cells were cultured for additional 1, 6 or 24 h with 10 or 100 nM EVE and then assayed for gene and protein expression. To evaluate the contribution of AKT-activation cells were pretreated (1 h before) with LY294002 (25 μM).
Gene expression analysis
Total RNA was extracted from the cell monolayer using the GenElute Mammalian Total RNA Miniprep kit (Sigma-Aldrich) including DNase treatment (DNase70; Sigma). Yield and purity were assessed using Nanodrop (EuroClone) and Agilent 2100 Bioanalyzer, respectively.
Primers sequence list
The cells were treated in lysis buffer (50 mMTris-HCl, pH 5.0, 150 mMNaCl,0.5 % Triton X-100) with Complete protease inhibitor mixture (Roche Applied Science) and phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich) and quantified using the Bio-Rad protein assay. Equal amounts of proteins were treated in reducing sample buffer and denatured for 10 min at 100 °C. Protein samples were then resolved in 10 % SDS-PAGE and electro transferred to nitrocellulose membranes. Nonspecific binding was blocked for 2 h at room temperature with nonfat milk (5 %) in TBST buffer (50mMTris-HCl, pH 7.4, 150 mM NaCl, 0.1Tween 20). Membranes were exposed to primary antibody overnight at4 °C and incubated with a secondary peroxidase-conjugated antibody for 1 h at room temperature. The primary antibodies were sc-9068 for FN, sc-130619 for alpha-SMA, sc-25778 for GAPDH, sc-7985-R for pAKT (SantaCruz Biotechnology) and GTX121937 for AKT (GeneTex). The signal was detected with the Super Signals West Pico Chemiluminescent substrate solution (Pierce) according to the manufacturer’s instructions. Bands of three independent experiments were analyzed by the Image J software (National Institutes of Health) to obtain mean values.
High doses of EVE activate HSC
High doses of EVE activate the EMT program in hepatocarcinoma cells
AKT activation induced by EVE
Since several studies suggested that mTORC1 inhibition by EVE may induce AKT activation leading to the attenuation of its therapeutic effects  and since AKT is an important signaling pathway involved in EMT we evaluated the effect of EVE in AKT activation.
Since their introduction in liver transplant therapy, mTOR inhibitors have been considered promising immunosuppressant due to their relatively low nephrotoxicity [2, 25]; the use of EVE is gaining acceptance as maintenance in de novo liver transplant, in cases of renal dysfunction as a CNI-sparing regimen and in patients transplanted for HCC [25, 26]. The main mechanism of action of this drug is the inhibition of cell signaling through the PI3K/Akt/mTOR pathway [27, 28]. The PI3K/AKT/mTOR signaling pathway represents a promising target due to its central role in regulating different cellular activities, including growth, survival, movement, differentiation and metabolism . Since the main mechanism of action of EVE is the inhibition of mTORC1 complex, its efficacy might be due to a feedback activation of upstream PI3K signaling, leading to AKT hyperactivation . AKT feedback is thought to be mediated by the inhibition of p70S6 kinase activity and different mechanisms of its activation have been proposed . An increase in the phosphorylation of receptor tyrosine kinases, i.e. EGFR, HER2, HER3 among others, following treatment with mTOR-I has been demonstrated and may represent an IRS-1-(insulin receptor substrate 1) independent way of increased AKT signaling. As regards, Rosich et al reported that the activity of EVE is limited by AKT re-phosphorylation and suggested that targeting the PI3K/AKT/mTOR pathway at multiple levels is likely to be a more effective strategy for the treatment of mantle cell lymphoma . Thus, despite the known antifibrotic EVE activity, an aberrant signaling with a negative feedback loop might result in the AKT activation following mTOR inhibition; this might be translated into the activation of cellular processes such as EMT. In fact, as we previously showed, high concentrations of EVE could induce renal fibrosis by activating tubular EMT . Therefore, to evaluate whether EVE treatment was able to interfere with the liver extracellular microenvironment by inducing EMT in rat stellate cell (HSC) and human liver cancer cell lines (HepG2), we measured, by RT-PCR, changes in expression level of genes encoding for well known EMT markers (α-SMA, Fibronectin and Vimentin) after both low-therapeutic (10 nM) and high (100 nM) doses; low dose has been considered therapeutic as it corresponds to the usual serum range (3-8 ng/mL) in the liver transplant setting. Our results demonstrated that the treatment with the therapeutic concentration 10 nM did not modify the gene expression of α-SMA, VIM and FN both after six and 24 h. These data confirm that EVE remains a potential inhibitor of liver fibrosis at therapeutic concentration, inhibiting collagen production by activated stellate cells, as well as cell contraction. Therefore, though therapeutic dose might attenuate the activation of primary stellate cells to their activated form, the treatment with 100 nM EVE (which is higher than the recommended through level in the liver transplant) significantly induced an increase in α-SMA, VIM and FN expression. Similarly, as regards HepG2 cell line, the therapeutic dose (10 nM EVE) did not induce alterations in α-SMA, VIM and FN gene expression. On the other hand 100 nM EVE induced a significant up-regulation of all the three mesenchymal markers already after six hours (Fig. 3).
These data suggest that progression of liver fibrosis represents a complex process that involves several pathological events (HSC activation, inflammation etc); on this basis the inhibition of multiple pathological processes using a single drug might be uneffective. Then, though our results are in line with several published papers reporting potential anti-fibrotic liver properties of both mTOR-I , however different unknown mechanisms could influence pAKT/AKT signal. Western blot analysis of pAKT/AKT confirmed that a high dosage of EVE (100 nM) induces the phosphorylation of AKT both in HSC and HepG2 cells causing EMT.
Moreover, TGF-β expression is up-regulated by high dose of EVE (100 nM EVE) after six hours both in HSC and HepG2 (Fig. 6). Since EVE concentration (e.g, 100 nM) able to induce EMT is higher compared to that normally used in standard immunosuppressive regimens, our data might not imply any clinical consequence.
Despite this consideration, in our opinion, our results highlight a relevant aspect of this drug. Interestingly, although EMT-related effects were reached in our model only with very high concentration of this drug (beyond the recommended clinical serum level) we cannot exclude that other different stimuli or patients with a genetic predisposition could present this condition after exposure to lower or therapeutic dose of EVE. This assumption is in line with a recent work published by Xu et al describing a pro-fibrotic effect of mTOR inhibitors in lung epithelial cells .
Altogether, our data, although obtained by an in vitro model, reveal new biological/cellular aspects of the liver and systemic pro-fibrotic machinery induced by EVE treatment; if confirmed by additional studies, they could be useful for researchers to develop new therapeutic strategies that may prevent/minimize the systemic fibrotic adverse effects induced by high doses EVE therapy. A negative feedback loop resulting in the activation of AKT following mTOR inhibition might also represent a potentially unfavorable event resulting from cancer treatment with mTOR inhibitors. As regards, the phosphorylation of AKT pathway at S473 is detected in up to 71 % of HCC samples, and associated with invasion, metastasis, and vascularization of HCC as showed by Chen e al . On the other hand, the EMT program sustained by AKT feedback-activation may interfere with malignant cell/microenvironment interactions, thanks to its involvement in essential processes such as migration, invasiveness and cytokine signaling. Though laboratory cell experimental studies are good models to study the genetics of cancer, however they might not permit to clarify and to understand the epigenetic surrounding the carcinogenesis. Despite this consideration, that aspect is linked to several clinical trials sustained at present whose emerging data indicate that RAD001, even well tolerated, has only moderate antitumor efficacy in HCC patients [35, 36].
The mechanisms by which immunosuppressive drugs can influence neoplasia is complex; and, as suggested by Bugelski et al, the identification of the relative risk for patients from preclinical data remains problematic. On the other hand, classifying immunosuppressive drugs based on their mechanism of action and hazard identification from preclinical studies to monitor carcinogenic risk may be a feasible way to manage patient safety .
In fact, antineoplastic properties of mTOR-I seem to be limited and might be enhanced by the contemporary inhibition of the crosstalk among mTORC1, mTORC2 and Phosphatidylinositol-3 kinase (PI3K)/AKT [8, 38].
Our in vitro study reveals new biological/cellular aspects of the pro-fibrotic activity of EVE and it demonstrates, for the first time, that an EMT program in parenchymal and non-parenchymal liver cells may be activated by high doses of this drug. Additionally, these data, confirming previous evidence , suggest that clinicians should administer the adequate dosage of EVE in order to increase efficacy and reduce adverse effects. Further studies are needed about PI3K/Akt/mTOR pathway may prevent the EMT process EVE-dependent and optimized its antitumor effect.
Liver EMT and consequent fibrosis is characterized by an orchestrated, highly regulated process. Altogether, our data, although obtained in an in vitro model, reveal new biological/cellular aspects of the liver and systemic pro-fibrotic machinery induced by high-dose EVE treatment; if confirmed by additional studies, they could be useful for researchers to develop new therapeutic strategies that may increase efficacy and reduce potential adverse affects of EVE also in the field of cancer.
This research was partially supported by Novartis Grant (Current Research Funds to Umberto Tedeschi).
This work was supported by Novartis grant.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol. 2005;139:2–10.View ArticlePubMedPubMed CentralGoogle Scholar
- Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer, and transplantation. Am J Transplant. 2008;8:2212–8.View ArticlePubMedGoogle Scholar
- Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc. 2007;39:2937–50.View ArticlePubMedGoogle Scholar
- Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunnuosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335–40.View ArticlePubMedGoogle Scholar
- Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–23.View ArticlePubMedGoogle Scholar
- Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, et al. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer. 2009;100:971–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, et al. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis. Cancer Med. 2013;2:862–71. Review.View ArticlePubMedPubMed CentralGoogle Scholar
- Cen P, Amato RJ. Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. Onco Targets Ther. 2012;5:217–24.PubMedPubMed CentralGoogle Scholar
- Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol. 2006;45:786–96.View ArticlePubMedGoogle Scholar
- Piguet AC, Majumder S, Maheshwari U, Manjunathan R, Saran U, Chatterjee S, et al. Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities. Clin Sci (Lond). 2014;126:775–84.View ArticleGoogle Scholar
- Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, Czaja A, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006;44:489–501.View ArticlePubMedGoogle Scholar
- Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf. 2013;12(2):177–86.View ArticlePubMedGoogle Scholar
- Stallone G, Infante B, Grandaliano G, Gesualdo L. Management of side effects of sirolimus therapy. Transplantation. 2009;87(8 Suppl):S23–6.View ArticlePubMedGoogle Scholar
- Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011;47(9):1287–98.View ArticlePubMedGoogle Scholar
- Morelon E, Stern M, Israel B, Correas JM, Danel C, Mamzer-Bruneel MF, et al. Characteristics of sirolimus associated interstitial pneumonitis in renal transplant patient. Transplantation. 2001;72(5):787–90.View ArticlePubMedGoogle Scholar
- Errasti P, Izquierdo D, Martín P, Errasti M, Slon F, Romero A, et al. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc. 2010;42(8):3053–4.View ArticlePubMedGoogle Scholar
- Rodríguez-Moreno A, Ridao N, García-Ledesma P, Calvo N, Pérez-Flores I, Marques M, et al. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc. 2009;41(6):2163–5.View ArticlePubMedGoogle Scholar
- Alexandru S, Ortiz A, Baldovi S, Milicua JM, Ruíz-Escribano E, Egido J, et al. Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant. 2008;23(10):3353–5.View ArticlePubMedGoogle Scholar
- Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A. Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med. 2013;11:292.View ArticlePubMedPubMed CentralGoogle Scholar
- van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene. 2009;28:4022–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R. TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci. 2012;125:1259–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang X, Yu WP, Gao L, Wei KB, Ju JL, Xu JZ. Effects of lipopolysaccharides stimulated Kupffer cells on activation of rat hepatic stellate cells. World J Gastroenterol. 2004;10:610–3.View ArticlePubMedPubMed CentralGoogle Scholar
- Masola V, Zaza G, Secchi MF, Gambaro G, Lupo A, Onisto M. Heparanase is a key player in renal fibrosis by regulating TGF-β expression and activity. Biochim Biophys Acta. 2014;1843:2122–8.View ArticlePubMedGoogle Scholar
- O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Klintmalm GB, Nashan B. The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant. 2014;2014:845438. 2014 Feb 25 Review.PubMedPubMed CentralGoogle Scholar
- Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27:1039–49.View ArticlePubMedGoogle Scholar
- Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer. 2012;11:85.View ArticlePubMedPubMed CentralGoogle Scholar
- Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C, et al. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin. Mol Cancer. 2014;13:2.View ArticlePubMedPubMed CentralGoogle Scholar
- Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res. 2006;66:3963–6.View ArticlePubMedGoogle Scholar
- Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19:58–71.View ArticlePubMedPubMed CentralGoogle Scholar
- Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932–40.View ArticlePubMedGoogle Scholar
- Rosich L, Xargay-Torrent S, Lopez-Guerra M, Campo E, Colomer D, Roue G. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clin Cancer Res. 2012;18:5278–89.View ArticlePubMedGoogle Scholar
- Xu X, Wan X, Geng J, Li F, Yang T, Dai H. Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Exp Biol Med (Maywood). 2013;238(9):1082–94.View ArticleGoogle Scholar
- Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res. 2009;39:177–86.View ArticlePubMedGoogle Scholar
- Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014;312(1):57–67.View ArticlePubMedGoogle Scholar
- Rizell M, Andersson M, Cahlin C, Hafstrom L, Olausson M, Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol. 2008;13:66–70.View ArticlePubMedGoogle Scholar
- Bugelski PJ, Volk A, Walker MR, Krayer JH, Martin P, Descotes J. Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol. 2010;29(5):435–66.View ArticlePubMedGoogle Scholar
- Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231–41.View ArticlePubMedPubMed CentralGoogle Scholar
- Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol. 2013;2013:403280.View ArticlePubMedPubMed CentralGoogle Scholar